Dive/SC (Surveillance Council) confirmed on Monday evening (4) the confirmation of the first case of Covid-19 EG.5 Eris in the state. The infected patient is a 37-year-old male. He lives in Biguaçu, in Greater Florianopolis.

The patient lives in Biguaçu and has no travel history, the Dive statement emphasizes – Photo: Arquivo/Leo Munhoz/ND

The infected person has no travel history and has a Covid-19 primary vaccination schedule (first and second doses). “On July 24, he sought medical attention at the HRSJ (San Jose Regional Hospital) with mild symptoms of a runny nose, muscle pain and headache,” the report said.

On the same day of the consultation, the institution’s sentinel unit collected the material and sent it to Lasen/CL (Central Public Health Laboratory). After the infection was confirmed, the agency sent a sample to the Fiocruz laboratory (Oswaldo Cruz Foundation) in Rio de Janeiro.

Fiocrus performed genetic sequencing and confirmed positive for the Eris EG.5 variant on Monday evening (4).

Eris variant

As reporter Gabriela Ferrares revealed, Eris has become the dominant variant in the US, with the WHO (World Health Organization) classifying its existence as “of interest”, that is, having “advantages” over other virus mutations. .

Eris has become the dominant variant in the US, and the WHO (World Health Organization) has classified its existence as “of interest”, i.e. having “advantages” over other virus mutations.

On August 19, the Ministry of Health released a technical note saying that despite the virus being in the “low risk” category, Eris has already been identified in 51 countries.

Diving advice/SC

Dive/SC reinforces the following recommendations:

• Vaccination is the main preventive measure;
• Vaccination against Covid-19 remains the best way to prevent serious cases, hospitalizations and deaths from the disease. Beyond the primary calendar (first and second doses), it is important that the entire population update their vaccination status with a booster;
• All populations aged 18 years and older receiving the full primary regimen (first and second doses) should receive a booster dose of bivalent, provided the last dose was more than 4 months old; This
• In addition to this group, people aged 12 years and older from the following priority groups can also receive bivalent revaccination: immunocompromised patients, people with comorbidities, the population of the indigenous population and quilombola communities, pregnant women and puerperals (mothers up to 45 days). postpartum), health professionals, persons with permanent disabilities, the incarcerated population, adolescents serving welfare measures, and prison staff